These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30298562)

  • 1. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma.
    Ito M; Miyata Y; Kushitani K; Yoshiya T; Kai Y; Tsutani Y; Mimura T; Konishi K; Takeshima Y; Okada M
    Thorac Cancer; 2018 Dec; 9(12):1594-1602. PubMed ID: 30298562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
    Ito M; Miyata Y; Tsutani Y; Ito H; Nakayama H; Imai K; Ikeda N; Okada M
    Lung Cancer; 2020 Mar; 141():107-113. PubMed ID: 32035371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Study of Surgical Treated Lung Adenocarcinoma with Ground Glass Nodule Component.
    Xu Y; Zheng M; Wang N; Wang R
    Med Sci Monit; 2019 Nov; 25():8492-8498. PubMed ID: 31710020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intense Expression of EGFR L858R Characterizes the Micropapillary Component and L858R Is Associated with the Risk of Recurrence in pN0M0 Lung Adenocarcinoma with the Micropapillary Component.
    Kishi N; Ito M; Miyata Y; Kanai A; Handa Y; Tsutani Y; Kushitani K; Takeshima Y; Okada M
    Ann Surg Oncol; 2020 Mar; 27(3):945-955. PubMed ID: 31732945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
    Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
    J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
    Ito M; Miyata Y; Kushitani K; Ueda D; Takeshima Y; Okada M
    BMC Cancer; 2023 Mar; 23(1):248. PubMed ID: 36918771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma.
    Hayasaka K; Shiono S; Matsumura Y; Yanagawa N; Suzuki H; Abe J; Sagawa M; Sakurada A; Katahira M; Takahashi S; Endoh M; Okada Y
    Ann Thorac Surg; 2018 Jun; 105(6):1648-1654. PubMed ID: 29486179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
    Takamochi K; Oh S; Matsunaga T; Suzuki K
    J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.
    Kondo Y; Ichinose J; Ninomiya H; Hashimoto K; Matsuura Y; Nakao M; Ishikawa Y; Okumura S; Satoh Y; Mun M
    Interact Cardiovasc Thorac Surg; 2022 Jul; 35(2):. PubMed ID: 35266536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
    Isaka T; Nakayama H; Ito H; Yokose T; Yamada K; Masuda M
    BMC Cancer; 2018 Oct; 18(1):959. PubMed ID: 30290774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
    Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
    Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.
    Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinctive clinicopathological features of adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung: A retrospective study.
    Ishida H; Shimizu Y; Sakaguchi H; Nitanda H; Kaneko K; Yamazaki N; Yanagihara A; Taguchi R; Sakai F; Yasuda M; Kobayashi K
    Lung Cancer; 2019 Mar; 129():16-21. PubMed ID: 30797486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction for prognosis of resected pT1a-1bN0M0 adenocarcinoma based on tumor size and histological status: relationship of TNM and IASLC/ATS/ERS classifications.
    Ito M; Miyata Y; Kushitani K; Yoshiya T; Mimae T; Ibuki Y; Misumi K; Takeshima Y; Okada M
    Lung Cancer; 2014 Aug; 85(2):270-5. PubMed ID: 24976332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of EGFR Mutation Status to Metabolic Activity in Localized Lung Adenocarcinoma and Its Influence on the Use of FDG PET/CT Parameters in Prognosis.
    Kim YI; Paeng JC; Park YS; Cheon GJ; Lee DS; Chung JK; Kang KW
    AJR Am J Roentgenol; 2018 Jun; 210(6):1346-1351. PubMed ID: 29547059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
    Isaka T; Ito H; Yokose T; Saito H; Adachi H; Murakami K; Miura J; Kikunishi N; Rino Y
    BMC Cancer; 2022 Sep; 22(1):966. PubMed ID: 36085020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?
    Han G; Bi J; Tan W; Wei X; Wang X; Ying X; Guo X; Zhou X; Hu D; Zhen W
    Oncotarget; 2016 Aug; 7(35):56998-57010. PubMed ID: 27486770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
    Qian F; Yang W; Wang R; Xu J; Wang S; Zhang Y; Jin B; Yu K; Han B
    J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1227-1235.e2. PubMed ID: 29223834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
    Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
    BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.